Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-09-05
2006-09-05
Lewis, Patrick (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S042000, C514S045000, C514S046000, C514S047000, C514S048000, C514S049000, C514S050000, C514S051000, C514S052000
Reexamination Certificate
active
07101860
ABSTRACT:
This invention is directed to a method of preventing or treating diseases or conditions associated with platelet aggregation. The method is also directed to a method of treating thrombosis. The method comprises administering to a subject a pharmaceutical composition comprising a therapeutically effective amount of P2Y12receptor antagonist compound, wherein said amount is effective to bind the P2Y12receptors on platelets and inhibit ADP-induced platelet aggregation. The P2Y12receptor antagonist compounds useful for this invention include mononucleoside polyphosphates and dinucleoside polyphosphates of general Formula I, or salts thereof The present invention also provides compositions comprising mononucleoside polyphosphates and dinucleoside polyphosphates according to Formula Ia and Ib.
REFERENCES:
patent: 3321463 (1967-05-01), Moffatt et al.
patent: 4621076 (1986-11-01), Kuzuya et al.
patent: 5049550 (1991-09-01), Zamecnik
patent: 5654285 (1997-08-01), Ingall et al.
patent: 5721219 (1998-02-01), Ingall et al.
patent: 5747496 (1998-05-01), Cox et al.
patent: 5814609 (1998-09-01), Markland et al.
patent: 5955447 (1999-09-01), Ingall et al.
patent: 6166022 (2000-12-01), Brown et al.
patent: 6323187 (2001-11-01), Yerza et al.
patent: 6528640 (2003-03-01), Beigelman et al.
patent: 1407903 (1975-10-01), None
patent: WO 89/04321 (1989-05-01), None
patent: WO 92/01673 (1991-07-01), None
patent: WO 92/17488 (1992-10-01), None
patent: WO 94/18216 (1994-08-01), None
patent: WO 97/03084 (1997-01-01), None
patent: WO 98/28300 (1998-07-01), None
patent: WO 99/61012 (1999-12-01), None
patent: WO 00/33080 (2000-06-01), None
patent: WO 00/34283 (2000-06-01), None
patent: WO 01/19826 (2001-03-01), None
patent: WO 01/36421 (2001-05-01), None
patent: WO 01/39781 (2001-06-01), None
patent: PCT/US01/41818 (2002-03-01), None
Kim et al. Journal of Biological Chemistry (1994), vol. 269, pp. 6471-6477.
Hamilton, A. et al., “Design of Substrate-Site-Directed Inhibitors of Adenylate Kinase and Hexokinase. Effect of Substrate Substituents on Affinity for the Adenine Nucleotide Sites”,J. Med. Chem., 19:1371-1377 (1976).
Hiratsuka T., “Affinity Labeling of the Myosin ATPase with Ribose-Modified Fluorescent Nucleotides and Vanadate”,J. Biochem., 96:147-154 (1984).
Martin, P. et al., “Structure-Activity Studies of Analogs of β,γ-Methylene-ATP at P2x-Purinoceptors in the Rabbit Ear Central Artery”,Drug Development Research, 36: 153-165 (1995).
Metzker, M. et al., “Termination of DNA synthesis by novel3′-modified-deoxyribonucleoside 5′-triphophate”,Nucleic Acids Research, 22:4259-4267 (1994).
Pelicano, H. et al., “Study of the substrate-binding properties of bovine liver adenosine kinase and inhibition by fluorescent nucleoside analogues”,Eur. J. Biochem., 248:930-937 (1997).
Richard, J. and Frey, P.A., “Stereochemical Course of Thiophosphoryl Group Transfer Catalyzed by Adenylate Kinase”,J. Am. Chem. Soc., 100: 7757-7758 (1978).
Sekine, M. et al., “New Type of Chemical Oxidative Phosphorylation: Activation of Phosphonate Function by Use of Triisopropylbenzenesulfonyl Chloride”,Tetrahedron Letters, 1145-1148 (1997).
Zatorski, A. et al., “Chemical Synthesis of Benzamide Adenine Dinucleotide: Inhibition of Inosine Monophosphate Dehydrogenase (Types I and II)”,Journal of Medicinal Chemistry, American Chemical Society, 39:2422-2426 (1996).
Alessi, D. et al., “Synthesis and Properties of a Conformationally Restricted Spin-Labeled Analog of ATP and its Interaction with Myosin and Skeletal Muscle”Biochemistry(1992), 31(34), 8043-54.
Bujalowski, W. et al., “Structural Characteristics of the Nucleotide-Binding Site ofEscherichia coliPrimary Replicative Helicase DnaB Protein. Studies with Ribose and Base-Modified Fluorescent Nucleotide Analogs”Biochemistry(1994), 33(15), 4682-94.
Cardullo, R. A. et al., “Synthesis, Purification, and Characterization of 2,4,6-Trinitrophenyl-UDP-galactose: A Fluorescent Substrate for Galactosyltransferase”Analytical Biochemistry(1990), 188(2), 305-9.
Carvalho-Alves, P. et al., “Stoichiometric Photolabeling of Two Distinct Low and High Affinity Nucleotide Sites in Sarcoplasmic Reticulum ATPase”Journal of Biological Chemistry(1985), 260(7), 4282-7.
Chapal, J. et al., “Comparative effects of adenosine-5′-triphosphate and related analogs on insulin secretion from the rat pancreas”Fundamental&Clinical Pharmacology(1997), 11(6), 537-545.
Hiratsuka, Toshiaki, “Biological Activities and Spectroscopic Properties of Chromophoric and Fluorescent Analogs of Adenine Nucleoside and Nucleotides, 2′,3′-0-(2,4,6-Trinitrocyclohexadienylidene) Adenosine Derivatives”Biochimica et Biophysica Acta(1982), 719(3), 509-17.
Hiratsuka, Toshiaki, “Monitoring the Myosin ATPase Reaction Using a Sensitive Fluorescent Probe: Pyrene-Labeled ATP”Biophysical Journal(1997), 72(2, Pt. 1), 843-849.
Ikehara, M. et al., “III. Interaction Between Synthetic Adenosine Triphosphate Analogs and Actomyosin Systems”Biochimica et Biophysica Acta(1965), 100(2), 471-8.
Ikehara, M. et al., “Unusual Rapid Cleavage of Terminal Phosphate Group of N6-Disubstituted Adenosine 5′-Triphosphate (ATP)by Divalent Cation”Biochimica et Biophysica Acta(1964), 85(3), 512-515.
Kwiatkowski, A. et al., “Mapping of the Adenosine 5′-Triphosphate Binding Site of Type II Calmodulin-Dependent Protein Kinase”Biochemistry(1987), 26(24), 7636-40.
Lowe, G. et al., “Evidence of a Dissociative SN1(P) Mechanism of Phosphoryl Transfer by Rabbit Muscle Pyruvate Kinase”Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry(1972-1999) (1978), (12), 1622-30.
Marian, M., “Acetyl Derivatives of Nucleoside 5′-Triphosphates. I.”Microchemical Journal(1984), 29(2), 219-27.
Mayer, I. et al., “Interaction of Fluorescent Adenine Nucleotide Derivatives with the ADP/ATP Carrier in Mitochondria. 1. Comparison of Various 3′-O-Ester Adenine Nucleotide Derivatives”Biochemistry(1984), 23(11), 2436-42.
Murataliev, M. et al., “Interaction of mitochondrial F1-ATPase with trinitrophenyl derivatives of ATP. Photoaffinity labeling of binding sites with 2-azido-2′,3′-O-(2,4,6-trinitrophenyl)adenosine 5′-triphosphate”European Journal of Biochemistry(1995), 232(2), 578-85.
Oliveira, C. R. G. et al., “Interaction of Spin-Labeled Nucleotides with Sarcoplasmic Reticulum Adenosinetriphosphatase”Biochemistry(1988), 27(16), 5923-7.
Ray, S. et al., “Microenvironment at the Substrate Binding Subsite of the Active Site of UDPglucose 4-Epimerase from Kluyveromyces Fragilis Using a Fluorescent Analog of UMP”Indian Journal of Biochemistry&Biophysics(1992), 29(2), 209-13.
Seebregts, C. et al., “2′,3′-O-(2,4,6-Trinitrophenyl)-8-Azido-adenosine Mono-, Di-, and Triphosphates as Photoaffinity Probes of the Ca2+-ATPase of Sarcoplasmic Reticulum, Regulatory/Superfluorescent Nucleotides Label the Catalytic Site with High Efficiency”Journal of Biological Chemistry(1989), 264(4), 2043-52.
Soslau, G. et al., “Aggregation of Human and Canine Platelets: Modulation by Purine Nucleotides”Thrombosis Research(1993), 72(2), 127-37.
Thoenges D. et al., “Tight Binding of Bulky Fluorescent Derivatives of Adenosine to the Low Affinity E2ATP Site Leads to Inhibition of Na+/K+-ATPase. Analysis of Structural Requirements of Fluorescent ATP Derivatives with a Koshland-Nemethy-Filmer Model of Two Interacting ATP Sites”Journal of Biological Chemistry(Jan. 22, 1999), 274(4), 1971-8.
Vigne, P. et al., “Benzoyl ATP is an Antagonist of Rat and Human P2Y1Receptors and of Platelet Aggregation”Biochemical and Biophysical Research Communications(1999), 256(1), 94-97.
Ward, D. et al., “Photoinactivati
Boyer José L.
Douglass James G.
Olins Gillian M.
Yerxa Benjamin R.
Howrey LLP
Inspire Pharmaceuticals Inc.
Kung Viola T.
Lewis Patrick
University of North Carolina
LandOfFree
Composition and method for inhibiting platelet aggregation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition and method for inhibiting platelet aggregation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition and method for inhibiting platelet aggregation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3560303